胸苷激酶1对进展期食管鳞癌放疗的影响  

The clinical effect of serum thymidine kinase 1 levels in esophageal squamous cell carcinoma cases treated with radiotherapy

作　　者：杜兴龙[1] 徐元肃 魏洁[1] DU Xing-long;XU Yuan-su;WEI Jie(Department of Radiation Oneology, Chuzhou First People＇s Hospital, Chuzhou, Anhui 239000, Chin)

机构地区：[1]滁州市第一人民医院放疗科,安徽滁州239000

出　　处：《中华全科医学》2018年第5期732-735,共4页Chinese Journal of General Practice

基　　金：2016年安徽省卫生计生委科研计划项目(2016QK008)

摘　　要：目的探讨血清胸苷激酶1(TK1)与食管鳞癌放疗关系。方法用ELISA法检测50例健康者和50例食管鳞癌血清TK1值,比较2组之间差异。分析TK1阳性率与TNM分期,分化程度,病灶长度,造影类型之间关系。检测疗前,疗后1周,疗后1月血清TK1,分析与剂量,治疗模式,疗效之间关系。结果 TK1在食管癌组、健康组分别为(3.14±1.70)pmol/L、(1.29±0.66)pmol/L,P<0.05。TK1阳性率在高分化、中分化、低-未分化分别为36.4%,84.4%,71.4%(P<0.05)。在Ⅱ期、Ⅲ期、Ⅳ期为62.5%,64.9%,40.0%(P>0.05)。病灶>6 cm、≤6cm TK1阳性率分别为63.9%,57.1%(P>0.05)。髓质,溃疡,缩窄,腔内型为68.7%,57.1%,62.5%,66.6%(P>0.05)。同步放化组和单放组TK1(pmol/L)在疗前和疗后1周,疗后1月(2.35±0.86、1.81±0.57、1.13±0.46)和(2.60±1.43、1.59±0.64、1.10±0.56),P<0.05。54~59Gy组和60~66Gy组(2.33±0.91、1.83±0.55、1.07±0.33)和(2.57±1.34、1.63±0.63、1.12±0.57);CR、PR和SD组为(2.33±0.96,1.84±0.57,1.03±0.32);(4.89±1.37,1.64±0.65,1.13±0.59);(2.63±0.51,1.44±0.19,1.22±0.32),P>0.05。血清TK1在疗前和疗后1周,疗后1月之间差异无统计学意义(P>0.05)。结论血清TK1可以辅助诊断食管癌,对治疗、疗效判断具有临床参考意义。Objective To evaluate the relationship between serum thymidine kinase 1 （TK!） and esophageal squamous cell carcinoma （ESCC） treated with radiotherapy. Methods Via the enzyme-linked immunosorbent assay （ELISA） for the detection of the TK1 levels in 50 healthy eases and 50 ESCC cases, we analyzed the difference between the two groups. The positive rate of TK1 in ESCC cases was detected, and the relationship with TNM staging, differentiation de- gree, length of lesion and type of angiography was evaluated. The TK1 level variation of 50 patients with ESCC were com- pared before and after 1 week and 1 month treatment. The relationships between TK1 and radiotherapy Dose, treatment modalities and clinical therapeutic efficacy were evaluated. Results The TK1 （pmol/L） concentration in ESCC group was 3.14 ± 1.70, and the healthy group was 1.29 ± 0.66, P 〈 0.05. The positive rates of serum TK1 in well differentia- ted group, moderately differentiated group, low undifferentiated group were 36.4%, 84.4% and 71.4% respectively, P 〈0.05. In stage II , III and IV, they were 62.5% , 64.9% and 40.0% , P 〉0.05. The cases with lesion length 〉 6 cm and ≤6 cm accounted for 63.9% and 57.1% , P 〉 0.05. And medulla type, ulcer type, narrow type and cavity type cases were 68.7% , 57.1% , 62.5% , 66.6% （P 〉0.05）. The concentrations of TKI （pmol/L） in the groups with concurrent chemoradiotherapy and the radiotherapy were 2.35 ± 0.86, 1.81 ± 0.57, 1.13 ± 0.46, 2.60 ± 1.43, 1.59 ± 0.64, 1.10 ± 0.56 （P 〈 0.05） before treatment, 1 week and 1 month after the end of radiotherapy. In the groups of 54 - 59 Gy and 60 - 66 Gy, TK1 （pmol/L） levels were 2.33 ± 0.91, 1.83 ± 0.55, 1.07 ± 0.33, and 2.57 ± 1.34, 1.63 ±0.63,1.12 ±0.57 respectively, P 〉0.05. In the CR, PR and SD groups TK1 （pmol/L） were 2.33 ±0.96, 1.84 ±0.57, 1.03 ±0.32; 4.89 ±1.37, 1.64 ±0.65, 1.13 ±0.59; 2.63 ±0.51, 1.44±0.19 and 1.22 ±0.32, re- spectively, P 〉 0.05. Serum TK1 concentrations in each group befor

关 键 词：胸苷激酶 酶联免疫法 食管肿瘤 鳞癌 

分 类 号：R735.1[医药卫生—肿瘤] R730.55[医药卫生—临床医学]